Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Meng LiYiting XiongChen LiaoYunyan HeSijia DuanFengming YiYiping WeiWenxiong ZhangPublished in: Breast cancer research and treatment (2020)
For HR-positive advanced breast cancer patients, the combination of anastrozole and fulvestrant appears to be superior to anastrozole alone in extending PFS and OS, despite relatively serious AEs.
Keyphrases